Pharma

Your Article Summary

See Latest Articles

Astellas launches vaprisol (conivaptan hydrochloride injection) premixed in 5% dextrose for the treatment of hyponatremia
Astellas, 09/11/09

Astellas Pharma US, Inc. announced the commercial availability of Vaprisol Premixed in 5% Dextrose, a new premixed formulation. Discovered and developed by Astellas, Vaprisol, an arginine vasopressin receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients.1 Hyponatremia is a potentially life–threatening condition that occurs when the body's blood sodium level falls significantly below normal.2 Vaprisol Premixed was approved by the U.S. Food and Drug Administration in October 2008.

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09

Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche, 12/14/09

 See all of Medical Devices/Products